Compare QH & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | LGVN |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 7.8M |
| IPO Year | 2019 | 2021 |
| Metric | QH | LGVN |
|---|---|---|
| Price | $3.23 | $2.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $61.25 |
| AVG Volume (30 Days) | 2.3K | ★ 90.9K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | $46.15 |
| Revenue Next Year | N/A | $24.63 |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.48 |
| 52 Week High | $12.81 | $7.60 |
| Indicator | QH | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 49.56 |
| Support Level | $3.05 | $0.65 |
| Resistance Level | $4.07 | $7.30 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 69.84 | 37.17 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.